<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">OJPed</journal-id><journal-title-group><journal-title>Open Journal of Pediatrics</journal-title></journal-title-group><issn pub-type="epub">2160-8741</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.4236/ojped.2022.125084</article-id><article-id pub-id-type="publisher-id">OJPed-121402</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine&amp;Healthcare</subject></subj-group></article-categories><title-group><article-title>
 
 
  Childhood Idiopathic Nephrotic Syndrome: A Single-Center Hospital Study
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Abdoul</surname><given-names>Karim Doumbia</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Tati</surname><given-names>Simaga</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Adama</surname><given-names>Dembélé</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Mahamadou</surname><given-names>Salihou Baldé</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Hawa</surname><given-names>G. Diall</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Pierre</surname><given-names>Togo</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Aminata</surname><given-names>Doumbia</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Belco</surname><given-names>Maiga</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Karamoko</surname><given-names>Sacko</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Fatoumata</surname><given-names>Léonie Diakité</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Oumou</surname><given-names>Koné</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Oumar</surname><given-names>Coulibaly</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Ibrahim</surname><given-names>Ahamadou</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Mohamed</surname><given-names>Elmouloud Cissé</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Guédiouma</surname><given-names>Dembelé</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Fousseyni</surname><given-names>Traoré</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Hawa</surname><given-names>Konaré</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Amadou</surname><given-names>Touré</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Djènèba</surname><given-names>Konaté</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Lala</surname><given-names>N’Drainy Sidibé</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Leyla</surname><given-names>Maiga</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Abdoul</surname><given-names>Aziz Diakité</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Boubacar</surname><given-names>Togo</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff1"><addr-line>Department of Pediatrics of CHU Gabriel Touré, Bamako, Mali</addr-line></aff><pub-date pub-type="epub"><day>26</day><month>10</month><year>2022</year></pub-date><volume>12</volume><issue>05</issue><fpage>832</fpage><lpage>840</lpage><history><date date-type="received"><day>22,</day>	<month>October</month>	<year>2022</year></date><date date-type="rev-recd"><day>20,</day>	<month>November</month>	<year>2022</year>	</date><date date-type="accepted"><day>23,</day>	<month>November</month>	<year>2022</year></date></history><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  Introduction: 
  Idiopathic nephrotic syndrome (INS) is one of the leading causes of childhood morbidity worldwide. This study was undertaken to complete the epidemiological, clinical, therapeutic and evolutionary aspects of NIS in hospitalized patients. <b>Methodology: </b>We conducted a retrospective study of patients with childhood NIS who had been admitted to our department from January 2017 to December 2018. Diagnosis, remission and relapse of idiopathic NS were defined according to the recommendations of the French Society of Pediatric Nephrology. We included all patients aged 2 to 14 years presenting a NIS picture. <b>Results: </b>During the study period, 35 patients with idiopathic NS had been hospitalized, representing a frequency of 1% of patients hospitalized in the department. The sex ratio was 2.22. The average age of the patients was 7.5 &#177; 3.5 years. Generalized edema was observed in all our patients. Arterial hypertension (36%) and abdominal pain (24%), hematuria (9%) were the main associated signs. Malnutrition was present in 66%, urinary tract infection in 20% and malaria in 24%. Cortico-sensitivity was obtained in 86% of patients, 14% were cortico-resistant and 11% were cortico-dependent. Relapses (6%) had been observed among cortico-sensitive patients. The mortality rate was 11%. <b>Conclusion: </b>This study calls for more trials to better elucidate prognostic indicators and develop better therapeutic approaches adapted to epidemio-clinical contexts.
 
</p></abstract><kwd-group><kwd>INS</kwd><kwd> Children</kwd><kwd> Corticosteroids</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>1. Introduction</title><p>Idiopathic nephrotic syndrome (INS) is one of the most common chronic kidney diseases in children [<xref ref-type="bibr" rid="scirp.121402-ref1">1</xref>] [<xref ref-type="bibr" rid="scirp.121402-ref2">2</xref>]. It accounts for 90% of nephrotic syndromes in children before the age of 10 and 50% after this age [<xref ref-type="bibr" rid="scirp.121402-ref3">3</xref>]. NIS is characterized by massive albuminuria responsible for hypoalbuminemia, edema, hyperlipidemia and various complications including infectious and thromboembolic [<xref ref-type="bibr" rid="scirp.121402-ref4">4</xref>]. It is a universal disease that affects all races and all continents [<xref ref-type="bibr" rid="scirp.121402-ref2">2</xref>]. Several researchers believe that there are geographic and ethnic disparities [<xref ref-type="bibr" rid="scirp.121402-ref1">1</xref>] [<xref ref-type="bibr" rid="scirp.121402-ref2">2</xref>] [<xref ref-type="bibr" rid="scirp.121402-ref4">4</xref>].</p><p>In the United States and Europe, the annual incidence of nephrotic syndromes in children was estimated to be between 1 and 7 per 100,000 children [<xref ref-type="bibr" rid="scirp.121402-ref2">2</xref>] [<xref ref-type="bibr" rid="scirp.121402-ref4">4</xref>]. In the United Kingdom, a study had shown that NIS was 6 times more common in children of Asian origin than in European children [<xref ref-type="bibr" rid="scirp.121402-ref5">5</xref>]. In sub-Saharan Africa, nephrotic syndrome is the main cause of chronic renal failure and end-stage renal disease in children [<xref ref-type="bibr" rid="scirp.121402-ref6">6</xref>]. In multiracial countries, people of African descent have been shown to be at higher risk of developing steroid-resistant nephrotic syndrome [<xref ref-type="bibr" rid="scirp.121402-ref6">6</xref>] [<xref ref-type="bibr" rid="scirp.121402-ref7">7</xref>].</p><p>Nephrotic syndrome in children can be classified into 3 three groups: secondary, congenital and infantile or idiopathic [<xref ref-type="bibr" rid="scirp.121402-ref4">4</xref>]. The etiology of most childhood nephrotic syndromes remains unknown, although immunological, systemic or genetic implications have been reported by several studies [<xref ref-type="bibr" rid="scirp.121402-ref5">5</xref>]. Nephrotic syndromes can occur at any age, but begins most often (in 90% of cases) in children under 10 years of age, often after an infectious or allergic trigger [<xref ref-type="bibr" rid="scirp.121402-ref5">5</xref>]. Kidney biopsy is indicated in cases of atypia: child under 1 year or over 12 years old, macroscopic hematuria, severe arterial hypertension, extrarenal signs, hypocomplementemia, renal failure, positive hepatitis serology [<xref ref-type="bibr" rid="scirp.121402-ref6">6</xref>] [<xref ref-type="bibr" rid="scirp.121402-ref8">8</xref>] [<xref ref-type="bibr" rid="scirp.121402-ref9">9</xref>]. Pathologically, minimal glomerular lesions present the most common appearance.</p><p>Lack of equipment and personnel for the processing and interpretation of kidney biopsies is a major barrier across Africa and needs to be addressed [<xref ref-type="bibr" rid="scirp.121402-ref6">6</xref>]. The treatment of the first attack is based on corticosteroid therapy (prednisone) for several weeks [<xref ref-type="bibr" rid="scirp.121402-ref2">2</xref>] [<xref ref-type="bibr" rid="scirp.121402-ref3">3</xref>]. Nephrotic syndromes treatment guidelines developed in Western countries are not always applicable in low-resource settings [<xref ref-type="bibr" rid="scirp.121402-ref5">5</xref>] [<xref ref-type="bibr" rid="scirp.121402-ref6">6</xref>] [<xref ref-type="bibr" rid="scirp.121402-ref8">8</xref>]. Rational management is then based on knowledge of relevant epidemiological data [<xref ref-type="bibr" rid="scirp.121402-ref6">6</xref>] [<xref ref-type="bibr" rid="scirp.121402-ref9">9</xref>].</p><p>In this study, we sought to describe the epidemiological, diagnostic and evolutionary aspects of NIS in children hospitalized in a pediatric department.</p></sec><sec id="s2"><title>2. Methodology</title><p>This was a retrospective, single-center descriptive study conducted from January 1, 2017 to December 31, 2018 in the general pediatrics department of the Gabriel Tour&#233; University Hospital Center (Bamako, Mali). The general pediatrics department includes 4 units and 72 hospital beds. It receives an average of 2162 patients per year, 55% of whom are referred by peripheral health structures.</p><p>We included the medical records of all children hospitalized for idiopathic nephrotic syndrome during the study period. Patients with incomplete records and those with no or poor follow-up were excluded. Congenital and secondary nephrotic syndromes cases were also excluded.</p><p>The idiopathic character of the nephrotic syndromes was retained in front of a negative etiological assessment comprising a search for sickle cell anemia, lupus, diabetes, human immunodeficiency virus (HIV) and hepatitis B virus (HBV) [<xref ref-type="bibr" rid="scirp.121402-ref3">3</xref>].</p><p>Data collection was done on a survey form from medical records, the follow-up notebook and department registers. The parameters studied were age, sex, clinical signs, urinalysis results, estimated 24-hour urinary protein, serum creatinine, serum protein, response to corticosteroid therapy, occurrence of relapse, follow-up, progress under treatment and duration of treatment.</p><p>All the patients had been treated with corticosteroids by referring to the national care protocol (PNDS) &quot;idiopathic nephrotic syndrome in children&quot; established by the French Society of Pediatric Nephrology and the rare disease reference center INS of the child and adult [<xref ref-type="bibr" rid="scirp.121402-ref2">2</xref>] [<xref ref-type="bibr" rid="scirp.121402-ref8">8</xref>].</p><p>The initial treatment of the idiopathic nephrotic syndrome included prednisolone at a dose of 60 mg/m<sup>2</sup>/day (2 mg/kg/d) in 2 oral doses without exceeding 60 mg/d for 4 weeks.</p><p>Corticosensitivity was defined by the disappearance of proteinuria after four weeks of oral treatment with prednisone at a dose of 2 mg/kg/day or after 3 boluses of methylprednisolone at a dose of 1 g/1.73m<sup>2</sup> of body surface area per bolus [<xref ref-type="bibr" rid="scirp.121402-ref3">3</xref>].</p><p>In the event of corticosteroid sensitivity, continue with the same doses every other day for 2 months then reduction by quarter of the dose (0.5 mg/kg) every 15 days (i.e. approximately 4 and a half months of treatment).</p><p>In case of cortico-resistance or cortico-dependence, add Cyclophosphamide (2 - 3 milligrams/kilogram/day for 2 - 3 months). Corticoresistance was defined by the absence of remission eight days after methylprednisolone infusions. Corticodependency was defined as a relapse during the tapering of corticosteroid therapy or less than three months after stopping it [<xref ref-type="bibr" rid="scirp.121402-ref3">3</xref>].</p><p>Patients were seen every 2 to 4 weeks depending on their place of residence and the evolution of symptoms. Clinical and biological constants were assessed at each follow-up visit.</p><p>Data were analyzed using Statistical Software for the Social Sciences (SPSS), version 20.0.</p></sec><sec id="s3"><title>3. Results</title><sec id="s3_1"><title>3.1. Epidemiological Aspects</title><p>During the study period, 3744 children had been hospitalized in the general pediatrics department, 35 had an INS. The frequency of idiopathic nephrotic syndrome was 1%. <xref ref-type="table" rid="table1">Table 1</xref> shows the distribution of patients by age, gender and clinical outcomes of children at the time of admission to the service. The mean age of the patients was 7.5 &#177; 3.5 years. The age range was 2 to 14 years old.</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Distribution of patients by age, sex and clinical results</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  colspan="2"  >Variables</th><th align="center" valign="middle" >Workforce</th><th align="center" valign="middle"  colspan="2"  >Percentage</th></tr></thead><tr><td align="center" valign="middle"  rowspan="3"  >Age</td><td align="center" valign="middle" >2 to 5 years</td><td align="center" valign="middle" >12</td><td align="center" valign="middle"  colspan="2"  >34</td></tr><tr><td align="center" valign="middle" >6 to 10 years old</td><td align="center" valign="middle" >9</td><td align="center" valign="middle"  colspan="2"  >26</td></tr><tr><td align="center" valign="middle" >10 to 14 years old</td><td align="center" valign="middle" >14</td><td align="center" valign="middle"  colspan="2"  >40</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >Sex</td><td align="center" valign="middle" >Male</td><td align="center" valign="middle" >24</td><td align="center" valign="middle"  colspan="2"  >69</td></tr><tr><td align="center" valign="middle" >Feminine</td><td align="center" valign="middle" >11</td><td align="center" valign="middle"  colspan="2"  >31</td></tr><tr><td align="center" valign="middle"  rowspan="5"  >Consultation period</td><td align="center" valign="middle" >[3, 6 weeks]</td><td align="center" valign="middle" >13</td><td align="center" valign="middle" >37</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >[6, 9 weeks]</td><td align="center" valign="middle" >10</td><td align="center" valign="middle" >29</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >[9, 12 weeks]</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >[12, 15 weeks]</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >&gt;at 15 weeks</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >14</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle"  rowspan="10"  >Clinical signs</td><td align="center" valign="middle" >Edema</td><td align="center" valign="middle" >35</td><td align="center" valign="middle"  colspan="2"  >100</td></tr><tr><td align="center" valign="middle" >Malnutrition</td><td align="center" valign="middle" >23</td><td align="center" valign="middle"  colspan="2"  >66</td></tr><tr><td align="center" valign="middle" >hypertension</td><td align="center" valign="middle" >12</td><td align="center" valign="middle"  colspan="2"  >36</td></tr><tr><td align="center" valign="middle" >Abdominal pain</td><td align="center" valign="middle" >8</td><td align="center" valign="middle"  colspan="2"  >24</td></tr><tr><td align="center" valign="middle" >Respiratory distress</td><td align="center" valign="middle" >8</td><td align="center" valign="middle"  colspan="2"  >24</td></tr><tr><td align="center" valign="middle" >Cloudy urine</td><td align="center" valign="middle" >8</td><td align="center" valign="middle"  colspan="2"  >24</td></tr><tr><td align="center" valign="middle" >Hematuria</td><td align="center" valign="middle" >3</td><td align="center" valign="middle"  colspan="2"  >9</td></tr><tr><td align="center" valign="middle" >Fever</td><td align="center" valign="middle" >3</td><td align="center" valign="middle"  colspan="2"  >9</td></tr><tr><td align="center" valign="middle" >Oliguria</td><td align="center" valign="middle" >2</td><td align="center" valign="middle"  colspan="2"  >6</td></tr><tr><td align="center" valign="middle" >Altered Consciousness</td><td align="center" valign="middle" >1</td><td align="center" valign="middle"  colspan="2"  >3</td></tr></tbody></table></table-wrap><p>Children under 10 accounted for 60% of the workforce. The sex ratio was 2.22. Patients resided in rural areas in 54% of cases. The average consultation time was 52 days with extremes of 6 days and 188 days. Before their admission to our service, 24 children (67%) had been treated by traditional healers with medicinal plants.</p></sec><sec id="s3_2"><title>3.2. Clinical Aspects</title><p>Clinically, edema was the only reason for consultation. It was a generalized edema in 91% of cases. The main clinical signs associated with edema were hypertension (36%), abdominal pain (24%) and respiratory distress (24%). The urine dipstick had objectified hematuria in 9%, leukocyturia in 23% and bacteriuria in 23% of cases.</p></sec><sec id="s3_3"><title>3.3. Paraclinical aspects</title><p>Mean proteinuria was 132.8 &#177; 53 mg/kg/24h. It exceeded 100 mg/kg/24h in 77% of patients. Mean serum albumin was 13.25 &#177; 5 g/L. Serum creatinine was above 100 &#181;mol/l in 20% of cases. Creatinine was normal in all our patients. The complement C3 fraction measured in 15 patients was normal in all cases. C-reactive protein (CRP) was elevated in 69% of cases. Hyperleukocytosis (over 10,000 leukocytes/mm<sup>3</sup>) was observed in 43% of cases. The mean hemoglobin level was 9.8 &#177; 2.4 g/dl. The hemoglobin level was below 8 g/dl in 25% of patients. The mean globular volume (MCV) was less than 70 fl in 31% of cases. Thrombocytopenia was observed in 14% of patients.</p><p>A urinary tract infection had been objectified in 7 patients (20%). Thick film was positive in 24% of patients.</p></sec><sec id="s3_4"><title>3.4. Therapeutic and Evolutionary Aspects</title><p>All our patients had received corticosteroid therapy; diuretics were prescribed in 94% of patients and antibiotics in 87%. Deworming and calcium supplementation were systematic. The mean hospital stay was 24 &#177; 13.7 days.</p><p>Corticosensitivity was retained in 86% (n = 30) (<xref ref-type="table" rid="table2">Table 2</xref>). Cyclophosphamide was combined with corticosteroid therapy in one corticosteroid-dependent patient (3%). The complete remission rate was 67%. The evolution was marked by 4 deaths (11 patients).</p></sec></sec><sec id="s4"><title>4. Comments and Discussion</title><p>Despite the methodological limits of our study, in particular the retrospective</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Therapeutic and evolutionary aspects of idiopathic nephrotic syndrome</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  colspan="2"  >Variables</th><th align="center" valign="middle" >Workforce</th><th align="center" valign="middle" >Percentage</th></tr></thead><tr><td align="center" valign="middle"  rowspan="7"  >Treatments</td><td align="center" valign="middle" >Corticosteroid therapy</td><td align="center" valign="middle" >35</td><td align="center" valign="middle" >100</td></tr><tr><td align="center" valign="middle" >Diuretic</td><td align="center" valign="middle" >33</td><td align="center" valign="middle" >94</td></tr><tr><td align="center" valign="middle" >Antibiotic therapy</td><td align="center" valign="middle" >30</td><td align="center" valign="middle" >87</td></tr><tr><td align="center" valign="middle" >calcium channel blocker</td><td align="center" valign="middle" >7</td><td align="center" valign="middle" >20</td></tr><tr><td align="center" valign="middle" >IEC</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >9</td></tr><tr><td align="center" valign="middle" >Methylprednisolone Boulus</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >6</td></tr><tr><td align="center" valign="middle" >Cyclophosphamide</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >3</td></tr><tr><td align="center" valign="middle"  rowspan="4"  >Duration of hospitalization</td><td align="center" valign="middle" >[1 to 2 weeks]</td><td align="center" valign="middle" >10</td><td align="center" valign="middle" >29</td></tr><tr><td align="center" valign="middle" >[3 to 4 weeks]</td><td align="center" valign="middle" >16</td><td align="center" valign="middle" >46</td></tr><tr><td align="center" valign="middle" >[5 to 6 weeks]</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >17</td></tr><tr><td align="center" valign="middle" >&gt;at 6 weeks</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >8</td></tr><tr><td align="center" valign="middle"  rowspan="6"  >Become</td><td align="center" valign="middle" >Steroid sensitive</td><td align="center" valign="middle" >30</td><td align="center" valign="middle" >86</td></tr><tr><td align="center" valign="middle" >Complete remission</td><td align="center" valign="middle" >24</td><td align="center" valign="middle" >67</td></tr><tr><td align="center" valign="middle" >Steroid-dependent</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >11</td></tr><tr><td align="center" valign="middle" >Relapse</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >6</td></tr><tr><td align="center" valign="middle" >Steroid-resistant</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >14</td></tr><tr><td align="center" valign="middle" >deceased</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >11</td></tr></tbody></table></table-wrap><p>and monocentric nature, we were able to appreciate the epidemiological, clinical, paraclinical and therapeutic aspects of the idiopathic nephrotic syndrome in the general pediatrics department of the CHU-GT.</p><p>1) Epidemiology</p><p>NIS is a common universal disease in pediatric hospitals [<xref ref-type="bibr" rid="scirp.121402-ref10">10</xref>]. The frequency of NIS is highly variable in studies around the world. In our study, it was estimated at 1%. This rate was statistically close to that obtained in Congo Brazzaville by Moyen et al. (0.8%) [<xref ref-type="bibr" rid="scirp.121402-ref11">11</xref>] but slightly lower than the rate obtained by Keita et al. in Senegal (1.56%) [<xref ref-type="bibr" rid="scirp.121402-ref3">3</xref>].</p><p>2) Age</p><p>On admission, the average age of our patients was 7 years 5 months. Our results were similar to those of Kari et al. in Saudi Arabia but below the average reported by Moyen et al. who found 10 years and 8 months [<xref ref-type="bibr" rid="scirp.121402-ref11">11</xref>] [<xref ref-type="bibr" rid="scirp.121402-ref12">12</xref>]. According to the literature, NIS can occur at any age, but most often begins between 2 and 7 years of age, often after an infectious or allergic trigger [<xref ref-type="bibr" rid="scirp.121402-ref8">8</xref>]. The age of patients seems to be older in African countries, probably because it is rare to diagnose congenital and infantile nephrotic syndromes in sub-Saharan Africa [<xref ref-type="bibr" rid="scirp.121402-ref13">13</xref>]</p><p>3) Sex</p><p>Boys were more affected than girls in our study (sex-ratio = 2.22). This male preponderance had been reported in previous studies in Africa [<xref ref-type="bibr" rid="scirp.121402-ref9">9</xref>] [<xref ref-type="bibr" rid="scirp.121402-ref13">13</xref>] [<xref ref-type="bibr" rid="scirp.121402-ref14">14</xref>]. No reason had been advanced in the literature to explain this male predominance. The sex ratio was in most studies and depending on the geographical location between 1 (absence of male preponderance) and 3.8 (overwhelming majority of boys) [<xref ref-type="bibr" rid="scirp.121402-ref9">9</xref>] [<xref ref-type="bibr" rid="scirp.121402-ref13">13</xref>] [<xref ref-type="bibr" rid="scirp.121402-ref14">14</xref>]. The male preponderance tends to vanish as adolescence approaches [<xref ref-type="bibr" rid="scirp.121402-ref9">9</xref>] [<xref ref-type="bibr" rid="scirp.121402-ref14">14</xref>]. The majority of our patients lived in rural areas (54%), so it would be interesting to look for an interaction between SN and climatic factors and the use of pesticides or other products used in field work. The consultation delay was particularly long in our study because of cultural beliefs, poverty and ignorance [<xref ref-type="bibr" rid="scirp.121402-ref13">13</xref>].</p><p>4) Clinical data</p><p>In our study, edema was present in all patients; it was generalized in 91%. This state would be mainly due to the long delay of medical consultation. Arterial hypertension (HTA) due to stimulation of the renin-angiotensin-aldosterone (RAA) system was very common in our series (36%). Our results were similar to those noted in African studies [<xref ref-type="bibr" rid="scirp.121402-ref6">6</xref>] [<xref ref-type="bibr" rid="scirp.121402-ref15">15</xref>]. A Chinese study had shown a link between an age greater than 8 years at the onset of nephrotic syndromes and a high risk of hypertension and hematuria [<xref ref-type="bibr" rid="scirp.121402-ref16">16</xref>]. In our context, the complications would be mainly linked to the delay in diagnosis and adequate management [<xref ref-type="bibr" rid="scirp.121402-ref13">13</xref>] [<xref ref-type="bibr" rid="scirp.121402-ref10">10</xref>] [<xref ref-type="bibr" rid="scirp.121402-ref17">17</xref>].</p><p>5) Biological data</p><p>In our series, the average proteinuria was particularly massive (greater than 100 mg/kg/24h) and the excessive hypoalbuminuria (albuminemia &lt; 20 g/l). These two phenomena were associated with severe malnutrition constituting a factor of poor prognosis on the evolution of the nephrotic syndromes towards corticodependency or corticoresistance [<xref ref-type="bibr" rid="scirp.121402-ref3">3</xref>] [<xref ref-type="bibr" rid="scirp.121402-ref18">18</xref>]. Parasitic (malaria) and bacterial (respiratory and urinary) infections were very frequent. During the NS, the urinary leakage of immunoglobulins (useful in the defense against microbes) leads to an immune deficiency with a significant increase in the risk of infections responsible for recurrences in patients in remission and an inadequate response to corticosteroid therapy [<xref ref-type="bibr" rid="scirp.121402-ref19">19</xref>] [<xref ref-type="bibr" rid="scirp.121402-ref20">20</xref>]. Anemia and malnutrition were frequently observed in our patients. Their origin could be multifactorial, linked to significant urinary losses of EPO and transferrin but also to a deficiency in vitamins and trace elements which requires supplementation (vitamin D, zinc, iron) and an adapted diet [<xref ref-type="bibr" rid="scirp.121402-ref21">21</xref>] [<xref ref-type="bibr" rid="scirp.121402-ref22">22</xref>].</p><p>No kidney biopsy was performed in our patients. Renal biopsy (RPB) allows the precise identification of renal lesions and their nosological classification, the assessment of signs of severity, and the evaluation of the importance of chronic lesions [<xref ref-type="bibr" rid="scirp.121402-ref23">23</xref>].</p><p>6) Therapeutic and evolutionary aspects</p><p>The pathophysiological consequences of the nephrotic syndrome such as hypovolemia, acute renal failure, edema, hypercoagulation and infections were treated symptomatically according to the recommendations of the literature [<xref ref-type="bibr" rid="scirp.121402-ref3">3</xref>] [<xref ref-type="bibr" rid="scirp.121402-ref8">8</xref>]. In our study, the symptomatic treatments combined sodium restriction, a diet low in fast sugars, vitamin-calcium supplementation, anticoagulation in the event of a proven risk and, exceptionally, albumin infusions. Diuretics were prescribed with caution in patients with signs of intolerance or for the treatment of hypertension.</p><p>Corticosteroid therapy was the cornerstone of the management of our patients. It had achieved complete remission in 67% of patients. Relapses were observed in 6% of steroid-sensitive patients. These rates were lower than those reported by most African authors [<xref ref-type="bibr" rid="scirp.121402-ref13">13</xref>]. According to several authors, corticosteroid resistance is the main factor in the poor prognosis of NIS [<xref ref-type="bibr" rid="scirp.121402-ref10">10</xref>] [<xref ref-type="bibr" rid="scirp.121402-ref19">19</xref>] [<xref ref-type="bibr" rid="scirp.121402-ref24">24</xref>]. In our context marked by the poverty of the populations and the technical platform, non-compliance and delay in treatment had also been cited as one of the major causes of therapeutic failure in the event of idiopathic nephrotic syndrome [<xref ref-type="bibr" rid="scirp.121402-ref1">1</xref>] [<xref ref-type="bibr" rid="scirp.121402-ref25">25</xref>]. Despite several advances in pathophysiology, NIS remains a complex disease that requires new therapeutic approaches adapted to local contexts.</p></sec><sec id="s5"><title>5. Conclusions</title><p>NIS is a common condition in pediatrics. The majority of cases occur in school-aged children. Edema was the main clinical manifestation. It was generally associated with hypertension and hematuria. The course under corticosteroid therapy was marked by complete remission in the majority of cases. Relapses were not uncommon (11%). Cyclophosphamide had been used in a patient with corticosteroid-resistant nephrotic syndromes.</p><p>For optimum management, the treatment must be adapted according to the clinical presentation, the histopathology and the socio-economic conditions of the children.</p></sec><sec id="s6"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest regarding the publication of this paper.</p></sec><sec id="s7"><title>Cite this paper</title><p>Doumbia, A.K., Simaga, T., Demb&#233;l&#233;, A., Bald&#233;, M.S., Diall, H.G., Togo, P., Doumbia, A., Maiga, B., Sacko, K., Diakit&#233;, F.L., Kon&#233;, O., Coulibaly, O., Ahamadou, I., Ciss&#233;, M.E., Dembel&#233;, G., Traor&#233;, F., Konar&#233;, H., Tour&#233;, A., Konat&#233;, D., Sidib&#233;, L.N’D., Maiga, L., Diakit&#233;, A.A. and Togo, B. (2022) Childhood Idiopathic Nephrotic Syndrome: A Single-Center Hospital Study. Open Journal of Pediatrics, 12, 832-840. https://doi.org/10.4236/ojped.2022.125084</p></sec></body><back><ref-list><title>References</title><ref id="scirp.121402-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Wang, C.-S., Yan, J., Palmer, R., Bost, J., Wolf, M.F. and Greenbaum, L.A. (2017) Childhood Nephrotic Syndrome Management and Outcome: A Single Center Retrospective Analysis. International Journal of Nephrology, 2017, Article ID: 2029583.  
https://doi.org/10.1155/2017/2029583</mixed-citation></ref><ref id="scirp.121402-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Maalley, B., Wely, M., Abdelkafi, Y., Hsairi, M., et al. (2019) Prise en charge thérapeutique du syndrome néphrotique corticodépendant chez l’enfant. Journal de l’Information Médicale de Sfax, 31, 1-11.</mixed-citation></ref><ref id="scirp.121402-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Keita, Y., Lemrabott, A.T., Sylla, A., Niang, B., Ka, E.H.F., Dial, C.M., Ndongo, A.A., Sow, A., Moreira, C., Niang, A., Ndiaye, O., Diouf, B. and Sall, M.G. (2017) Idiopathic Nephrotic Syndrome (NIS) in Children in Dakar: About 40 Cases. Pan African Medical Journal, 26, Article 161.  
https://doi.org/10.11604/pamj.2017.26.161.10130</mixed-citation></ref><ref id="scirp.121402-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Davin, J.C. and Rutjes, N.W. (2011) Nephrotic Syndrome in Children: From Bench to Treatment. International Journal of Nephrology, 2011, Article ID: 372304.  
https://doi.org/10.4061/2011/372304</mixed-citation></ref><ref id="scirp.121402-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Sharples, P.M., Poulton, J. and White, R.H. (1985) Steroid Responsive Nephrotic Syndrome Is More Common in Asians. Archives of Disease in Childhood, 60, 1014-1017.  
https://doi.org/10.1136/adc.60.11.1014</mixed-citation></ref><ref id="scirp.121402-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Esezobor, C., Ademola, A.D., Adetunji, A.E., Anigilaje, E.A., Batte, A, Jiya Bello, F.N., Furia, F.F., Muoneke, U., McCulloch, M., Nourse, P., Obiagwu, P., Odetunde, O., Okyere, P., Solarin, A., Tannor, E.K., Noone, D., Gbadegesin, R. and Parekh, R.S. (2020) Management of Idiopathic Childhood Nephrotic Syndrome in Sub-Saharan Africa: Ibadan Consensus Statement. Kidney International, 99, 59-67. 
https://doi.org/10.1016/j.kint.2020.07.045</mixed-citation></ref><ref id="scirp.121402-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Asinobi, A.O., Ademola, A.D., Okolo, C.A and Yaria, J.O. (2015) Trends in the Histopathology of Childhood Nephrotic Syndrome in Ibadan Nigeria: Preponderance of Idiopathic Focal Segmental Glomerulosclerosis. BMC Nephrology, 16, Article No. 213. https://doi.org/10.1186/s12882-015-0208-0</mixed-citation></ref><ref id="scirp.121402-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Boyer, O., Baudouin, V., Bérard, E., Dossier, C., Audard, V., Guigonis, V. and Vrillon, I. (2017) Aspects cliniques du syndrome néphrotique idiopathique de l’enfant. Archives de Pédiatrie, 24, 1338-1343. https://doi.org/10.1016/j.arcped.2017.09.022</mixed-citation></ref><ref id="scirp.121402-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Ibadin, M.O. and Abiodun, P.O. (1998) Epidemiology and Clinicopathologic Characteristics of Childhood Nephrotic Syndrome in Benin-City, Nigeria. Journal of Pakistan Medical Association, 48, 235-238.</mixed-citation></ref><ref id="scirp.121402-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Ruin, M. (2016) Le syndrome néphrotique idiopathique de l’enfant à La Réunion. épidémiologie, description clinique et aspects évolutifs sur une période de 11 ans. Université de Bordeaux, Bordeaux, 17 p.    
https://dumas.ccsd.cnrs.fr/dumas-01346716</mixed-citation></ref><ref id="scirp.121402-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Moyen, G., Assambo-Nkieli, C., Fourcade, V. and Mpemba Nzingoula, S. (1993) Nephrotic Syndrome in Children in Brazzaville about 36 Cases. Medicine from Black Africa, 40, 381-382.</mixed-citation></ref><ref id="scirp.121402-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Kari, J.A. and Halawani, M. (2010) Treatment of Steroid Resistant Nephrotic Syndrome in Children. Saudi Journal of Kidney Diseases and Transplantation, 21, 484-487.</mixed-citation></ref><ref id="scirp.121402-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Aloni, M.N., Sysleyne, L.M., Ekulu, P.M., Babio, F.L., Ngiyulu, R.M. and Gini-Ehungu, J.L. (2014) The Challenges of Caring for Children with Nephrotic Syndrome in a Tertiary Institution in the Democratic Republic of Congo. Acta Paediatrica, 103, e365-e369. https://doi.org/10.1111/apa.12647</mixed-citation></ref><ref id="scirp.121402-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Anigilaje, E.A., Fashie, A.P. and Ochie, C. (2019) Childhood Nephrotic Syndrome at the University of Abuja Teaching Hospital, Abuja, Nigeria: A Preliminary Report Supports High Steroid Responsiveness. Sudanese Journal of Paediatrics, 19, 126-139.  
https://doi.org/10.24911/SJP.106-1547399573</mixed-citation></ref><ref id="scirp.121402-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Bakhiet, Y.M., Mudi, A., Khumalo, T., Moonsamy, G. and Levy, C. (2017) Idiopathic Nephrotic Syndrome in South African Children. African Health Sciences, 17, 1130-1136. https://doi.org/10.4314/ahs.v17i4.22</mixed-citation></ref><ref id="scirp.121402-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Mortazavi, F. and Khiavi, Y.S. (2011) Steroid Response Pattern and Outcome of Pediatric Idiopathic Nephrotic Syndrome: A Single-Center Experience in Northwest Iran. Therapeutics and Clinical Risk Management, 7, 167-171.  
https://doi.org/10.2147/TCRM.S19751</mixed-citation></ref><ref id="scirp.121402-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Kiberd, B.A. and Class, C.M. (2002) Cumulative Risk for Developing End-Stage Renal Disease in the US Population. Journal of the American Society of Nephrology, 13, 1635-1644. https://doi.org/10.1097/01.ASN.0000014251.87778.01</mixed-citation></ref><ref id="scirp.121402-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Jellouli, M., Brika, M., et al. (2016) Childhood Nephrotic Syndrome: Predictive Factors of Corticosteroid Dependence. Medical Tunisia, 94, 401-405.</mixed-citation></ref><ref id="scirp.121402-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">&amp;Ouml;zlü, S.G., Demircin, G., T&amp;ouml;kmeci, N., &amp;Ccedil;altik Yilmaz, A., Aydo&amp;#287, &amp;Ouml;., Bülbül, M. and &amp;Ouml;ner, A. (2015) Long-Term Prognosis of Idiopathic Nephrotic Syndrome in Children. Renal Failure, 37, 672-677. https://doi.org/10.3109/0886022X.2015.1010940</mixed-citation></ref><ref id="scirp.121402-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Franke, I., Aydin, M., Kurylowicz, L., Lopez, C.E.L., Ganschow, R., Lentze, M.J. and Born, M. (2019) Clinical Course &amp; Management of Childhood Nephrotic Syndrome in Germany: A Large Epidemiological ESPED Study. BMC Nephrology, 20, Article No. 45. https://doi.org/10.1186/s12882-019-1233-1</mixed-citation></ref><ref id="scirp.121402-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Vaziri, N.D. (2001) Erythropoietin and Transferrin Metabolism in Nephrotic Syndrome. American Journal of Kidney Diseases, 38, 1-8.  
https://doi.org/10.1053/ajkd.2001.25174</mixed-citation></ref><ref id="scirp.121402-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Shibasaki, T., Misawa, T., Matsumoto, H., et al. (19941) Characteristics of Anemia in Patients with Nephrotic Syndrome. Japanese Journal of Nephrology: Nihon Jinzo Gakkai Shi, 36, 896-901.</mixed-citation></ref><ref id="scirp.121402-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Mbarki, H., Belghiti, K.A., Harmouch, T., Najdi, A., Arrayhani, M. and Sqalli, T. (2016) Renal Needle Biopsy in the Department of Nephrology in Fez: Indications and Results in 522 Cases. Pan African Medical Journal, 24, Article 21. 
https://doi.org/10.11604/pamj.2016.24.21.3982</mixed-citation></ref><ref id="scirp.121402-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Nourbakhsh, N. and Mak, R.H. (2017) Steroid-Resistant Nephrotic Syndrome: Past and Current Perspectives. Pediatric Health, Medicine and Therapeutics, 8, 29-37. 
https://doi.org/10.2147/PHMT.S100803</mixed-citation></ref><ref id="scirp.121402-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Sylla, M., Dicko-Traoré, F., Doumbia, A.K., Coulibaly, A., Diakité, A.A., Sangaré, M., et al. (2018) Post-Infectious Acute Glomerulonephritis in Child: Epidemiological, Clinical and Evolutionary Aspects in Gabriel Touré Teaching Hospital in Mali. Open Journal of Pediatrics, 8, 366-374. https://doi.org/10.4236/ojped.2018.84036</mixed-citation></ref></ref-list></back></article>